First AD

Second AD

Experts on advanced RCC discuss the CONTACT-03 trial evaluating atezolizumab plus cabozantinib in patients with inoperable disease.

CONTACT-03: Atezolizumab Plus Cabozantinib in Advanced RCC

Genitourinary Cancers

EXE-22-OSD1273 - /clinical/genitourinary-cancer

The OncLive Genitourinary Cancer condition center page is a comprehensive resource for clinical news and expert insights across genitourinary (GU) malignancies, including renal cell carcinoma, urothelial carcinoma, and prostate cancer. This section features news articles, interviews in written and video format, and podcasts that focus on the evolving treatment paradigm of GU cancers and emerging research. 

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

ASCO GU 2024: Updates in the Treatment of Advanced Renal Cell Carcinoma

Peer Exchange

Sarah Cannon Research Institute

Cancer Centers

Partner

Memorial Sloan Kettering Cancer Center 

Yale Cancer Center

Experts on advanced RCC discuss the CONTACT-03 trial evaluating atezolizumab plus cabozantinib following immune checkpoint inhibitor treatment in patients with inoperable disease.

First-Line Treatments for Advanced Clear Cell RCC

Long-Term Follow-Up from CheckMate 214 in Advanced RCC

CheckMate 67T: Subcutaneous vs IV Nivolumab in Previously Treated Advanced RCC

Recent Subgroup Analyses from the CLEAR study in Advanced RCC

LEAP Study: Lenvatinib Plus Pembrolizumab in Patients With RCC and Brain Metastasis

Lenvatinib Plus Pembrolizumab Network Meta-Analysis and Outcomes with Cabozantinib in Advanced RCC

CheckMate 9ER: Nivolumab Plus Cabozantinib in Newly Diagnosed Advanced RCC

Clinical Pearls for Managing IO-TKI and IO-IO Toxicity in Advanced RCC

LITESPARK-003 and LITESPARK-024: Ongoing Belzutifan Research

Treatment Decisions in the Second Line and Beyond in Advanced Clear Cell RCC

Updates on LITESPARK-005 and LITESPARK-011 in Advanced RCC

Clinical Insights on Belzutifan in Advanced RCC

Overview of Non–Clear Cell RCC

TKI Monotherapy Data in Non–Clear Cell RCC

KEYNOTE-B61: Lenvatinib Plus Pembrolizumab in Non–Clear Cell RCC

Nivolumab Plus Cabozantinib in Non–Clear Cell RCC

Future Perspectives and Unmet Needs in Renal Cell Carcinoma